These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 32653263

  • 1. Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment.
    Tsaur I, Heidegger I, van den Bergh RCN, Bektic J, Borgmann H, Foti S, Hunting JCB, Kretschmer A, Ploussard G, Tilki D, Gandaglia G, Dotzauer R, EAU-YAU Prostate Cancer Working Party.
    Eur Urol Focus; 2021 Nov; 7(6):1308-1315. PubMed ID: 32653263
    [Abstract] [Full Text] [Related]

  • 2. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
    Tsaur I, Heidegger I, Bektic J, Kafka M, van den Bergh RCN, Hunting JCB, Thomas A, Brandt MP, Höfner T, Debedde E, Thibault C, Ermacora P, Zattoni F, Foti S, Kretschmer A, Ploussard G, Rodler S, von Amsberg G, Tilki D, Surcel C, Rosenzweig B, Gadot M, Gandaglia G, Dotzauer R, EAU-YAU Prostate Cancer Working Party.
    Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489
    [Abstract] [Full Text] [Related]

  • 3. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [Abstract] [Full Text] [Related]

  • 4. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S.
    World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
    [Abstract] [Full Text] [Related]

  • 5. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
    Ozaki K, Hatakeyama S, Narita S, Hata K, Yanagisawa T, Tanaka T, Togashi K, Hamaya T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Kimura T, Habuchi T, Ohyama C.
    World J Urol; 2023 Jan; 41(1):67-75. PubMed ID: 36520204
    [Abstract] [Full Text] [Related]

  • 6. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T.
    Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
    [Abstract] [Full Text] [Related]

  • 7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 8. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
    Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Habuchi T.
    Int J Clin Oncol; 2022 Sep; 27(9):1477-1486. PubMed ID: 35748967
    [Abstract] [Full Text] [Related]

  • 9. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
    Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI.
    Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
    [Abstract] [Full Text] [Related]

  • 10. Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy.
    Hara T, Terakawa T, Okamura Y, Bando Y, Furukawa J, Harada K, Nakano Y, Fujisawa M.
    Prostate; 2023 Sep; 83(13):1270-1278. PubMed ID: 37316357
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Jiménez N, Garcia de Herreros M, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, García-Esteve S, Rodríguez-Carunchio L, Trias I, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domènech M, Figols M, Carles J, Suárez C, Herrero Rivera D, González-Billalabeitia E, Cívico C, Sala-González N, Ruiz de Porras V, Ribal MJ, Prat A, Mellado B.
    Eur Urol Oncol; 2024 Aug; 7(4):954-964. PubMed ID: 38429210
    [Abstract] [Full Text] [Related]

  • 13. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
    Mager R, Savko O, Böhm K, Thomas A, Dotzauer R, Borgmann H, Jäger W, Thomas C, Haferkamp A, Höfner T, Tsaur I.
    Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
    [Abstract] [Full Text] [Related]

  • 14. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T.
    World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
    [Abstract] [Full Text] [Related]

  • 15. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
    Kafka M, Burtscher T, Fritz J, Schmitz M, Bektic J, Ladurner M, Horninger W, Heidegger I.
    World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
    [Abstract] [Full Text] [Related]

  • 16. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 17. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [Abstract] [Full Text] [Related]

  • 20. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.